1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pigmented Villonodular Synovitis - Drugs In Development, 2022, provides an overview of the Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Pigmented villonodular synovitis (PVNS) is a condition that causes the synovium. PVNS is characterized by inflammation and overgrowth of the joint lining. This affects the hip or knee. Symptoms include pain, swelling in the affected joint, locking, catching, and instability in the joint. Treatment includes surgery and radiation therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Pigmented Villonodular Synovitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Pigmented Villonodular Synovitis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pigmented Villonodular Synovitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II and Phase I stages are 5 and 1 respectively.
Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pigmented Villonodular Synovitis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Pigmented Villonodular Synovitis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pigmented Villonodular Synovitis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pigmented Villonodular Synovitis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pigmented Villonodular Synovitis (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pigmented Villonodular Synovitis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Pigmented Villonodular Synovitis - Overview
- Pigmented Villonodular Synovitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Pigmented Villonodular Synovitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Pigmented Villonodular Synovitis - Companies Involved in Therapeutics Development
- Bristol-Myers Squibb Co
- Merck KGaA
- Nippon Chemiphar Co Ltd
- Novartis AG
- Regeneron Pharmaceuticals Inc
- SynOx Therapeutics Ltd
- Pigmented Villonodular Synovitis - Drug Profiles
- avelumab - Drug Profile
- Product Description
- Mechanism Of Action
- cabiralizumab - Drug Profile
- Product Description
- Mechanism Of Action
- emactuzumab - Drug Profile
- Product Description
- Mechanism Of Action
- nilotinib - Drug Profile
- Product Description
- Mechanism Of Action
- vidutolimod - Drug Profile
- Product Description
- Mechanism Of Action
- zaltoprofen - Drug Profile
- Product Description
- Mechanism Of Action
- Pigmented Villonodular Synovitis - Dormant Projects
- Pigmented Villonodular Synovitis - Discontinued Products
- Pigmented Villonodular Synovitis - Product Development Milestones
- Featured News & Press Releases
- Jun 01, 2014: Roche to present phase I data on investigational cancer immunotherapy anti-CSF-1R (RG7155) antibody in patients with Pigmented Villonodular Synovitis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Pigmented Villonodular Synovitis, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pigmented Villonodular Synovitis - Pipeline by Bristol-Myers Squibb Co, 2022
- Pigmented Villonodular Synovitis - Pipeline by Merck KGaA, 2022
- Pigmented Villonodular Synovitis - Pipeline by Nippon Chemiphar Co Ltd, 2022
- Pigmented Villonodular Synovitis - Pipeline by Novartis AG, 2022
- Pigmented Villonodular Synovitis - Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Pigmented Villonodular Synovitis - Pipeline by SynOx Therapeutics Ltd, 2022
- Pigmented Villonodular Synovitis - Dormant Projects, 2022
- Pigmented Villonodular Synovitis - Discontinued Products, 2022
- Number of Products under Development for Pigmented Villonodular Synovitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bristol-Myers Squibb Co
- Merck KGaA
- Nippon Chemiphar Co Ltd
- Novartis AG
- Regeneron Pharmaceuticals Inc
- SynOx Therapeutics Ltd
